Ginkgo Bioworks
American biotechnology company
DNA NYSE
SEC CIK 1830214
Follow Ginkgo Bioworks
Weekly email: filings, results
Revenue, last quarter
$27.7M
−5.7% vs same quarter last year
Net income
−$41M
+49.2% vs same quarter last year
EPS, diluted
−$0.64
+55.9% vs same quarter last year
Operating cash flow
−$28.3M
+10.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $170.2M | −$313K |
| FY24 | $227M | −$547K |
| FY23 | $251.5M | −$893K |
| FY22 | $477.7M | −$2.1M |
| FY21 | $313.8M | −$1.8M |
| FY20 | $76.7M | −$126.6M |
| FY19 | $54.2M | −$119.3M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −185.3% | −0.2% |
| FY24 | −246.5% | −0.2% |
| FY23 | −343.8% | −0.4% |
| FY22 | −462.4% | −0.4% |
| FY21 | −582.6% | −0.6% |
| FY20 | −178.8% | −165.2% |
| FY19 | −132.1% | −220.2% |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$178.7M |
| FY24 | −$382.1M |
| FY23 | −$336.3M |
| FY22 | −$304.5M |
| FY21 | −$310.3M |
| FY20 | −$193.7M |
| FY19 | −$66.9M |
| FY18 | - |
- Ginkgo Bioworks
- Healthcare median
Show the numbers
| Year | Ginkgo Bioworks | Healthcare median |
|---|---|---|
| FY25 | −0.2% | −30.6% |
| FY24 | −0.2% | −47% |
| FY23 | −0.4% | −58% |
| FY22 | −0.4% | −80.4% |
| FY21 | −0.6% | −71.9% |
| FY20 | −165.2% | −62.2% |
| FY19 | −220.2% | −46.3% |
| FY18 | - | −49.6% |